Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Aug;27(8):1145-1150.
doi: 10.1016/j.cmi.2021.03.021. Epub 2021 Apr 2.

Fourteen-day survival among older adults with severe infection with severe acute respiratory syndrome coronavirus 2 treated with corticosteroid: a cohort study

Laure Gallay  1 , Viet-Thi Tran  2 , Elodie Perrodeau  2 , Nicolas Vignier  3 , Matthieu Mahevas  4 , Francesca Bisio  5 , Emmanuel Forestier  6 , Francois-Xavier Lescure  7 ; COCO-OLD (Collaborative cOhort COrticoteroids for OLD patients with COvid-19) study Group
Collaborators, Affiliations
Observational Study

Fourteen-day survival among older adults with severe infection with severe acute respiratory syndrome coronavirus 2 treated with corticosteroid: a cohort study

Laure Gallay et al. Clin Microbiol Infect. 2021 Aug.

Abstract

Objective: To assess the effectiveness of corticosteroids among older adults with coronavirus disease 2019 (COVID-19) pneumonia requiring oxygen.

Methods: We used routine care data from 36 hospitals in France and Luxembourg to assess the effectiveness of corticosteroids with at least 0.4 mg/kg/day equivalent prednisone (treatment group) versus standard of care (control group). Participants were adults aged 80 years or older with PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or CT scan images typical of COVID-19 pneumonia, requiring oxygen ≥3 L/min, and with an inflammatory syndrome (C-reactive protein ≥40 mg/L). The primary outcome was overall survival at day 14. In our main analysis, characteristics of patients at baseline (i.e. time when patients met all inclusion criteria) were balanced by using propensity-score inverse probability of treatment weighting.

Results: Among the 267 patients included in the analysis, 98 were assigned to the treatment group. Their median age was 86 years (interquartile range 83-90 years) and 95% had a SARS-CoV-2 PCR-confirmed diagnosis. In total, 43/98 (43.9%) patients in the treatment group and 84/166 (50.6%) in the control group died before day 14 (weighted hazard ratio 0.67, 95% CI 0.46-0.99). The treatment and control groups did not differ significantly for the proportion of patients discharged to home/rehabilitation at day 14 (weighted relative risk 1.12, 95% CI 0.68-1.82). Twenty-two (16.7%) patients receiving corticosteroids developed adverse events, but only 11 (6.4%) from the control group.

Conclusions: Corticosteroids were associated with a significant increase in the overall survival at day 14 of patients aged 80 years and older hospitalized for severe COVID-19.

Keywords: Coronavirus disease 2019; Corticosteroids; Elderly; Observational study; Therapeutic evaluation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves for survival in the inverse probability of treatment sample. Abbreviation: CTC, corticosteroid treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;25:693–704. doi: 10.1056/NEJMoa2021436. - DOI - PMC - PubMed
    1. Sterne J.A.C., Murthy S., Diaz J.V., Slutsky A.S., Villar J., Angus D.C. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330–1341. doi: 10.1001/jama.2020.17023. - DOI - PMC - PubMed
    1. Angus D.C., Derde L., Al-Beidh F., Annane D., Arabi Y., Beane A. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020;324:1317–1329. doi: 10.1001/jama.2020.17022. - DOI - PMC - PubMed
    1. Tomazini B.M., Maia I.S., Cavalcanti A.B., Berwanger O., Rosa R.G., Veiga V.C. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX Randomized Clinical Trial. JAMA. 2020;324:1307–1316. doi: 10.1001/jama.2020.17021. - DOI - PMC - PubMed
    1. Tran V.-T., Mahévas M., Bani-Sadr F., Robineau O., Perpoint O., Perrodeau E. Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. Clin Microbiol Infect. 2020;27:603–610. doi: 10.1016/j.cmi.2020.11.035. - DOI - PMC - PubMed

Publication types